Improving Outcomes for the Poor Prognosis Patient

Saturday 19 May | 13:30-14:25

Join us in Reykjavik for the 12th Biennial Alpha Conferencewhere the CooperSurgical Companies will be sponsoring a lunchtime symposium on ‘Improving Outcomes for Poor Prognosis Patients.’

Featuring presentations from experts in the field, the talks will discuss some of the options available to help you improve live pregnancy rates in your clinic.

HABSelect trial outcomes and more nuanced findings

David Miller, PhD (Reader in Molecular Andrology, Leeds University, UK)

David will open the symposium by discussing how enhanced sperm selection by hyaluronic acid binding, using the PICSI® Dishcan improve live birth rates and reduce miscarriage rates.

As Chief Investigator and Laboratory Lead of the HABSelect trial – a large, randomized study assessing the effectiveness of this method of sperm selection for ICSI – David will present trial outcomes and more nuanced findings from the study.

Experience and results with GM-CSF at the CARE clinics

Sue Montgomery, PhD (Laboratory Manager, Care Fertility, Manchester, UK)

Studies have shown that EmbryoGen® & BlastGenTM  can increase the chances of obtaining a live birth for poor prognosis patients. Designed to facilitate communication between embryo and endometrium, these unique products aim to minimize embryonic stress by creating a more physiological in vitro environment. In her talk, Sue will present real-world experience and results with EmbryoGen & BlastGen at the CARE clinics.

Genetic testing to improve outcomes for poor prognosis patients

David Chrimes, PhD (Business Development & Customer Management Excellence, CooperGenomics)

Rounding off the symposium, David will discuss how genetic testing can improve outcomes for poor prognosis patients. PGT-A (PGS) has been shown to reduce miscarriage rates and increase implantation and live birth rates, and this talk will explore how to interpret testing results, including a discussion on mosaicism.